A recent study published in The Lancet Infectious Diseases journal reveals that the use of metformin, a widely available and low-cost diabetes medication, reduces the risk of developing long COVID by 41 percent. 
Meanwhile, ivermectin, another drug that has been the subject of much debate and scrutiny, showed no significant impact on the incidence of long COVID.
Deep Dive Into the Study
The University of Minnesota spearheaded a large-scale, placebo-controlled study called COVID-OUT. The study aimed to determine whether administering metformin, ivermectin, or fluvoxamine during the early stages of COVID-19 outpatient treatment could decrease the likelihood of developing long COVID.
This expansive phase 3 trial spanned six sites across the United States. The researchers worked with a substantial participant pool of over 1,100 overweight or obese adults aged 30 and above. None of these individuals had been previously infected with COVID-19, and around half had received a COVID-19 vaccination. All participants experienced COVID-19 symptoms for less than a week and tested positive for the virus within three days before enrolling in the study….